---
title: "EW: Q2 sales up 12.5% year-over-year; guidance raised on strong TAVR and TMTT growth"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293676466.md"
description: "Q2 sales grew 12.5% year-over-year, driven by strong TAVR, TMTT, and surgical performance. Full-year sales guidance was raised to 10%-11%, with robust operating margins and EPS outlook. Key catalysts include new product launches, regulatory milestones, and expanded indications.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-23T23:12:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293676466.md)
  - [en](https://longbridge.com/en/news/293676466.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293676466.md)
---

# EW: Q2 sales up 12.5% year-over-year; guidance raised on strong TAVR and TMTT growth

Q2 sales grew 12.5% year-over-year, driven by strong TAVR, TMTT, and surgical performance. Full-year sales guidance was raised to 10%-11%, with robust operating margins and EPS outlook. Key catalysts include new product launches, regulatory milestones, and expanded indications.

Based on

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [EW.US](https://longbridge.com/en/quote/EW.US.md)

## Related News & Research

- [Edwards Earnings Add Fuel To Bullish MedTech Thesis, Analyst Says](https://longbridge.com/en/news/293778081.md)
- [Analyst Maintains Hold on Edwards with Neutral Risk-Reward and Reiterated $85 Price Target Amid Pending TAVR Catalysts](https://longbridge.com/en/news/293780167.md)
- [Abbott initiates clinical study to show outcomes for real-world use of TriClip™ in repairing leaky tricuspid heart valve](https://longbridge.com/en/news/294071737.md)
- [Top Executive Cashes In on Major Edwards Lifesciences Stock Move](https://longbridge.com/en/news/293997184.md)
- [Edwards Lifesciences Holding lifts Carvolix stake to 11.65% of capital, 9.07% voting rights](https://longbridge.com/en/news/293729797.md)